Clinical Trials Browser

Rituximab × Clear all

NCT04840602 2026-05-27

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05100862 2026-05-27

MAHOGANY

Phase 3 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06040320 2026-05-27

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin

NCT06337318 2026-05-27

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Phase 3 Recruiting

Classic Follicular Lymphoma

NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT06561360 2026-05-26

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06943872 2026-05-26

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00092222 2026-05-22

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2 Active not recruiting

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Phase 2 Completed

30 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01446133 2026-05-22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT02727803 2026-05-22

Personalized NK Cell Therapy in CBT

Phase 2 Recruiting

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT04002947 2026-05-22

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05139017 2026-05-22

waveLINE-003

Phase 2/3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05783609 2026-05-22

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT06717347 2026-05-22

MK-2140-010

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-22

MK-2140-011

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07601607 2026-05-22

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02007044 2026-05-20

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04765111 2026-05-20

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Phase 3 Recruiting

Lymphoma, Follicular

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT03805932 2026-05-19

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Phase 1 Active not recruiting

18 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04318678 2026-05-19

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia

NCT06091254 2026-05-19

OLYMPIA-1

Phase 3 Recruiting

Lymphoma, Follicular

NCT07226843 2026-05-19

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Phase 1 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04002297 2026-05-18

MANGROVE

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05947851 2026-05-18

BELLWAVE-010

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT05221645 2026-05-15

P+R-ICE

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05683171 2026-05-15

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Phase 1/2 Recruiting

Lymphoma

NCT06091865 2026-05-15

OLYMPIA-3

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06790420 2026-05-15

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

2,703 enrolled 13 charts

Infections, Lymphoma

NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04458610 2026-05-14

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06564038 2026-05-14

Soundtrack-E

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02160015 2026-05-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03321643 2026-05-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Phase 2/3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT06965114 2026-05-13

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

Phase 1 Not yet recruiting

Ann Arbor Stage II Mantle Cell Lymphoma

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, B-Cell

NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell